Boehringer Ingelheim Vetmedica Gmbh

Other

Gregory Brian Haiwick

Eric Martin Vaughn

Luis Alejandro Hernandez

Christine Margaret Muehlenthaler

Merrill Lynn Schaeffer

Marc Allan Eichmeyer

Jeremy Kroll

Troy James Kaiser

Fuad Tawfiq Haddadin

Ali Khazraeinazmpour

Caroline Ann Kohler

Guosong Zhao

Bernd Colin Eichenmueller

Andrea J Headrick Starks

Curtis Robert Edwards

Marta Noguera Serrat

Robert Thomas Cool

Sonja Klocke

Michael Landon Stewart

Sonia Regina Cantisano Malburg

Vaccination methods to control PCV2 infection with different PCV2 subtypes are disclosed. Specifically, a PCV2 subtype b (PCV2b) ORF2 proteins or immunogenic compositions comprising a PCV2b ORF2 protein are used in a method for the treatment or prevention of an infection with PCV2 of the same PCV2b and/or different subtype; the reduction, prevention or treatment of clinical signs caused by an infection with PCV2 of the same PCV2b or a different subtype; and/or the prevention or treatment of a disease caused by an infection with PCV2 of the same PCV2b and/or a different subtype. The present invention in particular relates to PCV2 subtype b (PCV2b) ORF2 proteins characterized in that they contain at least one mutation in the BC loop that such that the expressed protein is preferably expressed in a higher amount compared to a PCV2 ORF2 protein that does not contain such mutation.

PCV2 ORF2 protein variant and virus like particles composed thereof

The present invention relates to a porcine parvovirus and porcine reproductive and respiratory syndrome virus vaccine for protecting a subject, preferably swine, against diseases associated with porcine parvovirus and porcine reproductive and respiratory syndrome virus. The present invention further relates to methods of producing immunogenic compositions as well as such immunogenic compositions exhibiting reduced virucidal activity.

Methods of manufacturing an immunogenic composition comprising a recombinant protein

Vaccination methods to control PCVinfection with different PCVsubtypes are disclosed. Specifically, a PCVsubtype b (PCV2b) ORF2 proteins or immunogenic compositions comprising a PCV2b ORF2 protein are used in a method for the treatment or prevention of an infection with PCVof the same PCV2b and/or different subtype; the reduction, prevention or treatment of clinical signs caused by an infection with PCVof the same PCV2b or a different subtype; and/or the prevention or treatment of a disease caused by an infection with PCVof the same PCV2b and/or a different subtype. The present invention in particular relates to PCVsubtype b (PCV2b) ORF2 proteins characterized in that they contain at least one mutation in the BC loop that such that the expressed protein is preferably expressed in a higher amount compared to a PCVORFprotein that does not contain such mutation.

The present invention provides methods of reducing the virucidal activity of a composition comprising a PCV-2 antigen as well as antigenic preparations and immunogenic compositions comprising a PCV-2 antigen, wherein the virucidal activity has been reduced. In addition, the present invention also relates to a method of increasing the immunogenicity of an immunogenic composition comprising a PCV-2 antigen as well as immunogenic composition with an increased immunogenicity.

Methods of reducing virucidal activity in PCV-2 compositions and PCV-2 compositions with an improved immunogenicity

Growing community of inventors

Ankeny, IA, United States of America

Gregory Brian Haiwick